Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome

Maria Casal-Dominguez, Iago Pinal-Fernandez, Julio Huapaya, Jemima Albayda, Julie J. Paik, Cheilonda Johnson, Leeann Silhan, Andrew L. Mammen, Sonye K. Danoff, Lisa Christopher-Stine

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: To study the efficacy in terms of muscle strength, and corticosteroid tapering as well as the prevalence of adverse effects in patients with the antisynthetase syndrome (ASyS) treated with azathioprine (AZA) compared to those treated with methotrexate (MTX). METHODS: We compared the clinical outcomes in ASyS patients treated with AZA versus MTX including change in corticosteroid dose, strength, and creatine kinase (CK) as well as the prevalence of adverse effects. RESULTS: Among 169 patients with ASyS, 102 were treated at some point exclusively with either AZA or MTX (± corticosteroids). There were no significant differences in the rate of muscle strength recovery, CK decrease or corticosteroid tapering between those ASyS patients treated with MTX versus AZA. The prevalence of adverse events in patients treated with AZA and MTX was similar (29% vs. 25%, p>0.05); elevated liver enzymes (17% AZA vs. 12% MTX) and gastrointestinal involvement (10% AZA vs. 8% MTX) were the most common adverse events. While no patients treated with AZA developed lung complications, two of the patients treated with MTX experienced reversible pneumonitis with MTX cessation. CONCLUSIONS: AZA and MTX showed similar efficacy and adverse events in patients with ASyS. Pneumonitis is a rare but important event in patients receiving MTX.

Original languageEnglish (US)
Pages (from-to)858-861
Number of pages4
JournalClinical and experimental rheumatology
Volume37
Issue number5
StatePublished - Sep 1 2019
Externally publishedYes

Fingerprint

Azathioprine
Methotrexate
Adrenal Cortex Hormones
Muscle Strength
Creatine Kinase
Pneumonia
Antisynthetase syndrome
Lung

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Casal-Dominguez, M., Pinal-Fernandez, I., Huapaya, J., Albayda, J., Paik, J. J., Johnson, C., ... Christopher-Stine, L. (2019). Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. Clinical and experimental rheumatology, 37(5), 858-861.

Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. / Casal-Dominguez, Maria; Pinal-Fernandez, Iago; Huapaya, Julio; Albayda, Jemima; Paik, Julie J.; Johnson, Cheilonda; Silhan, Leeann; Mammen, Andrew L.; Danoff, Sonye K.; Christopher-Stine, Lisa.

In: Clinical and experimental rheumatology, Vol. 37, No. 5, 01.09.2019, p. 858-861.

Research output: Contribution to journalArticle

Casal-Dominguez, M, Pinal-Fernandez, I, Huapaya, J, Albayda, J, Paik, JJ, Johnson, C, Silhan, L, Mammen, AL, Danoff, SK & Christopher-Stine, L 2019, 'Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome', Clinical and experimental rheumatology, vol. 37, no. 5, pp. 858-861.
Casal-Dominguez M, Pinal-Fernandez I, Huapaya J, Albayda J, Paik JJ, Johnson C et al. Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. Clinical and experimental rheumatology. 2019 Sep 1;37(5):858-861.
Casal-Dominguez, Maria ; Pinal-Fernandez, Iago ; Huapaya, Julio ; Albayda, Jemima ; Paik, Julie J. ; Johnson, Cheilonda ; Silhan, Leeann ; Mammen, Andrew L. ; Danoff, Sonye K. ; Christopher-Stine, Lisa. / Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. In: Clinical and experimental rheumatology. 2019 ; Vol. 37, No. 5. pp. 858-861.
@article{98dc95c0f01e427ca212a5f19185d628,
title = "Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome",
abstract = "OBJECTIVES: To study the efficacy in terms of muscle strength, and corticosteroid tapering as well as the prevalence of adverse effects in patients with the antisynthetase syndrome (ASyS) treated with azathioprine (AZA) compared to those treated with methotrexate (MTX). METHODS: We compared the clinical outcomes in ASyS patients treated with AZA versus MTX including change in corticosteroid dose, strength, and creatine kinase (CK) as well as the prevalence of adverse effects. RESULTS: Among 169 patients with ASyS, 102 were treated at some point exclusively with either AZA or MTX (± corticosteroids). There were no significant differences in the rate of muscle strength recovery, CK decrease or corticosteroid tapering between those ASyS patients treated with MTX versus AZA. The prevalence of adverse events in patients treated with AZA and MTX was similar (29{\%} vs. 25{\%}, p>0.05); elevated liver enzymes (17{\%} AZA vs. 12{\%} MTX) and gastrointestinal involvement (10{\%} AZA vs. 8{\%} MTX) were the most common adverse events. While no patients treated with AZA developed lung complications, two of the patients treated with MTX experienced reversible pneumonitis with MTX cessation. CONCLUSIONS: AZA and MTX showed similar efficacy and adverse events in patients with ASyS. Pneumonitis is a rare but important event in patients receiving MTX.",
author = "Maria Casal-Dominguez and Iago Pinal-Fernandez and Julio Huapaya and Jemima Albayda and Paik, {Julie J.} and Cheilonda Johnson and Leeann Silhan and Mammen, {Andrew L.} and Danoff, {Sonye K.} and Lisa Christopher-Stine",
year = "2019",
month = "9",
day = "1",
language = "English (US)",
volume = "37",
pages = "858--861",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5",

}

TY - JOUR

T1 - Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome

AU - Casal-Dominguez, Maria

AU - Pinal-Fernandez, Iago

AU - Huapaya, Julio

AU - Albayda, Jemima

AU - Paik, Julie J.

AU - Johnson, Cheilonda

AU - Silhan, Leeann

AU - Mammen, Andrew L.

AU - Danoff, Sonye K.

AU - Christopher-Stine, Lisa

PY - 2019/9/1

Y1 - 2019/9/1

N2 - OBJECTIVES: To study the efficacy in terms of muscle strength, and corticosteroid tapering as well as the prevalence of adverse effects in patients with the antisynthetase syndrome (ASyS) treated with azathioprine (AZA) compared to those treated with methotrexate (MTX). METHODS: We compared the clinical outcomes in ASyS patients treated with AZA versus MTX including change in corticosteroid dose, strength, and creatine kinase (CK) as well as the prevalence of adverse effects. RESULTS: Among 169 patients with ASyS, 102 were treated at some point exclusively with either AZA or MTX (± corticosteroids). There were no significant differences in the rate of muscle strength recovery, CK decrease or corticosteroid tapering between those ASyS patients treated with MTX versus AZA. The prevalence of adverse events in patients treated with AZA and MTX was similar (29% vs. 25%, p>0.05); elevated liver enzymes (17% AZA vs. 12% MTX) and gastrointestinal involvement (10% AZA vs. 8% MTX) were the most common adverse events. While no patients treated with AZA developed lung complications, two of the patients treated with MTX experienced reversible pneumonitis with MTX cessation. CONCLUSIONS: AZA and MTX showed similar efficacy and adverse events in patients with ASyS. Pneumonitis is a rare but important event in patients receiving MTX.

AB - OBJECTIVES: To study the efficacy in terms of muscle strength, and corticosteroid tapering as well as the prevalence of adverse effects in patients with the antisynthetase syndrome (ASyS) treated with azathioprine (AZA) compared to those treated with methotrexate (MTX). METHODS: We compared the clinical outcomes in ASyS patients treated with AZA versus MTX including change in corticosteroid dose, strength, and creatine kinase (CK) as well as the prevalence of adverse effects. RESULTS: Among 169 patients with ASyS, 102 were treated at some point exclusively with either AZA or MTX (± corticosteroids). There were no significant differences in the rate of muscle strength recovery, CK decrease or corticosteroid tapering between those ASyS patients treated with MTX versus AZA. The prevalence of adverse events in patients treated with AZA and MTX was similar (29% vs. 25%, p>0.05); elevated liver enzymes (17% AZA vs. 12% MTX) and gastrointestinal involvement (10% AZA vs. 8% MTX) were the most common adverse events. While no patients treated with AZA developed lung complications, two of the patients treated with MTX experienced reversible pneumonitis with MTX cessation. CONCLUSIONS: AZA and MTX showed similar efficacy and adverse events in patients with ASyS. Pneumonitis is a rare but important event in patients receiving MTX.

UR - http://www.scopus.com/inward/record.url?scp=85072509244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072509244&partnerID=8YFLogxK

M3 - Article

C2 - 31074729

AN - SCOPUS:85072509244

VL - 37

SP - 858

EP - 861

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5

ER -